Acute myeloid leukemia: advancing clinical trials and promising therapeutics
Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy.
Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.
In many circumstances the response rates with such targeted or antibody‑based therapies are superior to those achieved with standard therapy and with decreased toxicity.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Can natural killer cells cure leukemia?
- MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance
- Advancing Leukemia Diagnosis and Treatment: WHO-Supported Laboratory Innovations in Africa- A Narrative Review
- Immunotherapy for leukemia may change the bone marrow environment, cancer researchers find
- Next-generation CAR‑T therapy for acute myeloid leukemia: bridging innovation with clinical translation